The likely detrimental variants at loci SLC9A9 and STRN4 associate with increased AD risk, Braak, Thal, CSF p-Tau, and/or plasma p-Tau levels, while the likely beneficial variants at loci SCIN, NPAS3, and ITGB4 associate with decreased Thal and CSF p-Tau levels, increased CSF amyloid levels, and/or trending with decreased amyloid PET measures. This evidence concerns the gene MAPT and Alzheimer disease.